First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...

How breast cancer research is helping prostate cancer patients

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, ...
Cure Today

First Patient Enrolled in Phase 3 Recurrent Prostate Cancer Trial

The PROSTATE-IQ trial uses the ArteraAI Prostate Test to personalize treatment for prostate cancer recurrence post-prostatectomy, potentially reducing hormone therapy use. The trial stratifies ...
Nasdaq

Cortechs.ai and EDAP TMS SA Announce Successful First OnQ Prostate-Assisted Focal One® HIFU Procedure at UCSF Prostate Cancer Center

The first OnQ Prostate-assisted Focal One® Robotic HIFU procedure was successfully performed at UCSF, improving prostate cancer treatment precision. Cortechs.ai and EDAP TMS have announced the ...